Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients with an IDH2 Mutation

Multiple Cancer Types

This trial studies the side effects of enasidenib and to see how well it works in treating patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with chemotherapy (refractory). Patients must also have a specific genetic change, also called a mutation, in a protein called IDH2. Enasidenib may stop the growth of cancer cells by blocking the mutated IDH2 protein, which is needed for cell growth.
Pediatric Leukemia, Pediatrics
II
Zarnegar-Lumley, Sara
NCT04203316
COGADVL18P1

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: